GlassScriptPhysician profile
Everitt N Simmons
NPI 1952333064
$1,354.14
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $594 · 2020: $403 · 2021: $243 · 2022: $114.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organogenesis INC. | $894.61 | 2019-2022 | |
| Smith+Nephew, INC. | $101.54 | 2019-2021 | |
| Abbvie INC. | $81.05 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $62.64 | 2021 | |
| Kci USA, INC. | $44.14 | 2020 | |
| Bsn Medical INC | $27.89 | 2022 | |
| Integra Lifesciences Corporation | $25.61 | 2019-2020 | |
| Hydrofera LLC | $22.05 | 2021 | |
| Bioventus LLC | $17.70 | 2022 | |
| Melinta Therapeutics, LLC | $16.85 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $16.11 | 2019 | |
| Medline Industries LP | $15.71 | 2021 | |
| Osiris Therapeutics INC. | $15.56 | 2019 | |
| Allergan, INC. | $12.68 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Everitt Simmons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.